Management of Gaucher disease: Enzyme replacement therapy

Pediatric Endocrinology Reviews

Volumn 12, Issue , 2014, Pages 82-87

  Zimran, Ari ^a   Elstein, Deborah ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Enzyme Replacement Therapy (ERT); Gaucher disease; Glucocerebrosidase; Imiglucerase; Taliglucerase alfa; Velaglucerase alfa

Indexed keywords

ALGLUCERASE; HEMOGLOBIN; IMIGLUCERASE; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA; GLUCOSYLCERAMIDASE;

ANEMIA; ARTICLE; BONE DENSITY; BONE NECROSIS; BONE RADIOGRAPHY; CORTICAL BONE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; ENZYME REPLACEMENT; GAUCHER DISEASE; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HUMAN; LIVER WEIGHT; LONGEVITY; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLEEN WEIGHT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRAL CONTAMINATION; REVIEW; TREATMENT OUTCOME;

ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84908224658     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Brady RO. Thesphingolipidoses. N Engl J Med 1966; 275(6):312-318
2. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker Rl, Argoff CE, and collaborators. Replacement therapy for inherited enzyme deficiency-Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-1468
3. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-37
4. Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995;34:1479-1480
5. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-118
6. Brady RO. Enzyme replacement for lysosomal diseases. Ann Rev Med 2006;57:283-284
7. Zimran A, Bembi B, Pastores G. Enzyme replacement therapy for type I Gaucher disease. In: Futerman AH, Zimran A, editors. Gaucher disease. Florida: CRC Press, Florida, 2007: 341 pp
8. Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet. Med 2009;11:92-99
9. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160(18):2835-2843
10. Weinreb NJ Advances in Gaucher disease: Therapeutic goals and evaluation and monitoring guidelines. Semin Hematol 2004; 41 (4 Suppl 5):1
11. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymanska A. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41(4 Suppl 5):4-14
12. Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Amer J Hematol 2008;83(12):890-895
13. Rosenthal Dl, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier R, McKusick KA, Rosen BR, Baker J, Niklason LT, Hill SC, and collaborators. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995;96(4 Pt 1):629-637
14. Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, Weinreb NJ, Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002;75 Suppl 1:A25-36
15. Fleshner PR, Aufses AH Jr, Grabowski GA, Elias R. A 27-year experience with splenectomy for Gaucher's disease. Am J Surg 1991;161(1):69-75
16. Zimran A, Elstein D, Schiffmann R, Abrahamov A, Goldberg M, ; Bar-Maor, J.A.; Brady, R.O.; Guzzetta, P.C.; Barton, N.W. Outcome of partial splenectomy for type I Gaucher disease. J. Pediatr., 1995, 126(4), 596-597
17. Zimran A, Abrahamov A, Elstein D. Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr MedAssocJ2000;2(2):80-81
18. Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91-98
19. Bove KE, Daugherty C, Grabowski GA. Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol 1995;26(9):1040-1045
20. Davies EH, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J Inherit Metab Dis 2007;30(6):935-942
21. Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, Brady RO, Barton NW, Schiffmann R. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr 2001;138:539-545
22. Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007;90:157-1
23. Zhao H, Bailey LA, Grabowski GA. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis 2003;30(1):90-96
24. Zimran A, Hollak CEM, Abrahamov A, van Oers MH, Kelly M, Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: An international collaborative study of 33 patients. Blood 1993;82:1107-1109
25. Elstein D, Granovsky-Grisaru S, Rabinowitz R, Kanai R, Abrahamov A, Zimran A. Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 1997;177:1509-1512
26. Langeveld M, de Fost M Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 2008;40(3):428-432
27. Rosenbloom BE, Weinreb NJ Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005;105:4569-4572
28. Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry PK, The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit Metab Dis 2010; 33(2):16M73
29. Lian Y, Elstein D, Zimran A. Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. Immunol Cell Biol 2009;87(7):514-524
30. Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM. Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010;44(1):41-47
31. Zimran A, Loveday K Fratazzi C, Elstein D. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2007;39:115-117
32. Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS ONE 2009; 4792: 4e
33. Zimran A, Altarescu G, Phillips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D. Phase I /11 and Extension Study of velaglucerase alfa (Gene-Activated™ Human Glucocerebrosidase) Replacement Therapy in Adults with Type 1 Gaucher Disease: 48 Month Experience. Blood, 2010;115(23):4651-4656
34. Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis. 2011;46(1):119-123
35. Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis. 2011;47(1):56-61
36. Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013;88(3):166-171
37. Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013;88(3):172-178
38. Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 2013;88(3):179-184
39. Bracoud L, Ahmad H, Brill-Almon E, Chertkoff R. Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model. Blood Cells Mol Dis. 2011;46(1):47-52
40. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Terreros Muñoz E, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D. Pivotal trial with plant-cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):5767-5773
41. van Dussen L, Zimran A, Akkerman EM, Aerts JM, Petakov M, Elstein D, Rosenbaum H, Aviezer D, Brill-Almon E, Chertkoff R, Maas M, Hollak CE. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood Cells Mol Dis. 2013;50(3):206-211
42. Protalix boasts of "revolutionary" advance on oral Gaucher's drug-FierceBiotech http://www.fiercebiotech.com/story/protalix-boasts-revolutionary-advance-oral-gauchers-drug/2011-01-20#ixzz1DpLOcJtG